Reported Earlier, Belite Bio Secures $25M In Registered Direct Offering With Institutional Investors
Reported Earlier, Belite Bio Secures $25M In Registered Direct Offering With Institutional Investors
Belite Bio entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an aggregate of 651,380 American Depositary Shares of the Company ("ADSs"), each ADS representing one ordinary share of the Company at a purchase price of $38.38 per ADS, and the warrants to purchase up to an aggregate of 651,380 ADSs, which will have an initial exercise price equal to $44.14 per ADS and will be immediately exercisable and expire on the five-year anniversary of the issuance, in a registered direct offering. The closing of the offering is expected to occur on or about April 30, 2024, subject to the satisfaction of customary closing conditions.
Belite Bio與一家機構投資者簽訂了證券購買協議，以購買和出售公司總共651,380股美國存托股份（“ADS”），每股ADS代表公司的一股普通股，每股ADS的收購價爲38.38美元，以及總共購買651,380股ADS的認股權證，其初始行使價等於每股ADS44.14美元，將在註冊直接發行中可立即行使並在發行五週年之日到期。此次發行預計將於2024年4月30日左右結束，但須滿足慣例成交條件。
譯文內容由第三人軟體翻譯。